康莱特注射液治疗原发性肺癌的临床研究被引量：59

A clinical study for the effect of the patients with primary lung cancer treated by post-operative adjuvant therapy with Chinese medicine Kang-Lai-Te.

在线阅读下载PDF

导出

摘要目的研究康莱特注射液对肺癌手术患者机体免疫力及机体恢复状况的影响。方法选非小细胞肺癌患者86例,采集手术前及用康莱特注射液治疗后静脉抗凝血,用流式细胞仪检测T细胞亚群CD3+,CD4+,CD8+,及CD4+/CD8+比值和NK细胞的比例变化;用卡氏计分法观察治疗前后患者的机体恢复及生活质量状况。结果非小细胞肺癌患者术前T细胞亚群及其CD4+/CD8+比值和NK细胞均较正常人减低(P<0.05),术后给予康莱特治疗半月后与手术前相比较CD3+、CD4+、NK、CD4+/CD8+细胞有显著提高(P<0.01),均达到或接近正常对照组无显著性差异水平(P>0.05);患者生活质量的KPS评分改善率达82.0%、体重增加率87.5%,均高于未给药的空白对照组66.7%和70.0%,差异显著(P>0.05)。结论康莱特注射液可提高肺癌患者术后的机体免疫力及生存质量,能够促进肺癌患者术后健康恢复,是术后早期既有抗肿瘤作用又能促进术后免疫力及健康恢复的药物。 Objective To study immunity and live quality of operated patients with primary tung cancer treated by post - operative adjuvant therapy with Chinese medicine Kang - Lai - Te. Methods The level of CD3^ ＋ , CD4^ ＋ , CD8^ ＋ , CD4^ ＋/CD8^ ＋ and NK cells in vein blood of the patients was detected by FCM pre -operation and following the post - operative adjuvant therapy with Kang - Lai - Te. The post - operative live quality of patients treated with and without Kang - Lai - Te was evaluated by KPS method. Results The level of CD3^ ＋ , CD4^ ＋ , CD8^ ＋ , CD4^ ＋ / CD8^ ＋ and NK cells of the patients before operation was lower than that in the normal subjects. It was increased significantly, almost reached the normal subjects, after operation following the post -operative adjuvant therapy with Kang - Lai - Te （ P 〈 0.01 ）. The post - operative survival quality evaluated by KPS and ration of the body weight increasing of the patients treated with anti without Kang - Lai - Te was （ 82.0% , 87.5% ） much higher than that （ 66. 7% , 70.0% ） in the control group without administration of Kang - Lai - Te. Conclusion Kang - Lai - Te is able to improve the immunity and live quality of operated patients with primary tung cancer and enhance the postoperative recovery of the patients.

作者王云杰黄立军张志培王小平

机构地区第四军医大学唐都医院

出处《现代肿瘤医学》 CAS 2006年第1期36-37,共2页 Journal of Modern Oncology

基金康来特药业有限公司研究资助项目

关键词肺癌康莱特免疫 T细胞亚群生存质量 lung cancer, Kang - Lai - Te, immunity, T - cells, survival quality

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献4

1[2]Smyth MT,Kershaw MH,Trapani TA.Xenospeicfic cytotoxic T lymphocytes:potent lysis in vitro and in vivo [J].Transplantation,1997,63(8) :1171 ～ 1178.
2[3]Frey AB,Cestari S.Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4 + anti - tumor T cells requires tumor expression of cell surface MHC class Ⅱ molecules[J].Cells- Immunol,1997,178 (1) :5728 ～ 5735.
3[4]Salvadori S,Martinelli G,Zier K.Resection of solid tumor reverses T cell defects and restores protective immunity [J].J Immunol,2000,164(4) :2214 ～ 2220.
4[5]Bronte V,Chappell DB,Apolloni E,et al.Unopposed production of granulocyte - macrophage colony - stimulating factor by tumors inhibits CD8 + T cell responses by dysregulating antigen - presenting cell maturation [J].J Immunol,1999,162 (10):5728 ～5737.